42% of online pharmacies offering semaglutide, a key ingredient in Wegovy, operate without valid licenses and sell drugs without prescriptions, per a JAMA Network Open study.

42% of online pharmacies offering semaglutide, a key ingredient in Novo Nordisk's anti-obesity drug Wegovy, operate without valid licenses and sell drugs without prescriptions, a JAMA Network Open study reveals. Counterfeit weight loss drugs purchased from these unauthorized sources expose patients to risks of receiving unsafe and ineffective products, containing low-purity semaglutide, excessive dosages, and in some cases, bacterial contamination. The study highlights the risks associated with obtaining these drugs from unauthorized sources due to high prices, lack of insurance coverage, and drug shortages.

August 02, 2024
4 Articles